Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
4
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
4
×
san francisco blog main
4
×
san francisco top stories
biotech
clinical trials
fda
akcea therapeutics
alnylam pharmaceuticals
avapritinib
blueprint medicines
eli lilly
genentech
hereditary transthyretin amyloidosis
inotersen
medullary thyroid cancer
new york blog main
new york top stories
non-small cell lung cancer
patisiran
pralsetinib
rna interference
roche
san diego blog main
san diego top stories
selpercatinib
tafamidis
thyroid cancer
vyndaqel
andrew fire
barry greene
boston university
cancer
cancer drugs
capmatinib
craig mello
What
fda
4
×
drug
alnylam
approval
blueprint
cancer
medicine
medicines
ret
address
afternoon
ago
alnylam’s
approve
approved
approves
awaits
biological
candidate
carries
certain
crossed
currently
decades
decision
designed
discovered
fingers
friday
genetic
gets
historic
history
landmark
latest
making
marketing
muscle
ok
onpattro
Language
unset
Current search:
boston
×
fda
×
" national top stories "
×
" san francisco blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision